Oncology Data Advisor
CME | MOC | NCPD | ILNA
Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, incuding the safety and tolerabilty of emerging treatments, survivorship care, and much more. This podcast is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Yale School of Medicine and Smilow Cancer Hospital. Listen to the podcast now.
In this episode of Oncology Data Advisor TM, learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Listen now!
This episode of Oncology Data Advisor™ will focus on strategies for the management of differentiated and anaplastic thyroid cancer, including emerging data on immunotherapies and strategies to manage adverse events. This podcast is presented by leading experts, Jochen Lorch, MD, MSc, Director of the Thyroid Cancer Center, Dana-Farber Cancer Institute, and Carolyn Grande, CRNP, AOCNP®, Oncology Nurse Practitioner, Abramson Cancer Center. Listen now to earn free CME | NCPD.
This episode of Oncology Data AdvisorTM will focus on new and emerging treatment strategies for advanced classical Hodgkin lymphoma, personalized care plans, and best practices for managing supportive care needs. This podcast is presented by leading experts Kami Maddocks, MD, Professor of Clinical Internal Medicine, Lymphoma Program Director, The James Cancer Hospital at The Ohio State University, and Kelly Brassil, PhD, RN, FAAN, Advanced Practice Nurse, University of Texas MD Anderson Cancer Center. Listen now to earn free CME | NCPD.
This episode of Oncology Data AdvisorTM will focus on advances in the treatment of relapsed or refractory immune thrombocytopenia. It features perspectives from two noted experts in the field: Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse, John Theurer Cancer Center, Hackensack Meridian Health.
In this podcast episode, discover new developments in the diagnosis and treatment of EGFR exon-20 Insertion–Mutant NSCLC and assess emerging efficacy and safety data on novel targeted therapies. This podcast features expert insights from Helena Yu, MD, Memorial Sloan Kettering Cancer Center, and Maria Arcila, MD, Memorial Sloan Kettering Cancer Center. Listen now to earn free CME | NCPD.
On this episode of Oncology Data AdvisorTM, Mitesh J. Borad, MD, shares insights on managing cholangiocarcinoma in a discussion that covers the changing treatment landscape, adverse events of concern with novel therapies, and advice for members of the cancer care team as they seek to optimize outcomes for patients with this disease.
On this bonus episode of Oncology Data AdvisorTM, Bradley McGregor, MD, and Robert Motzer, MD, discuss first-line and second-line treatments for advanced renal cell carcinoma. Also available as a video. Listen now and earn CME/NCPD credit!
On this bonus episode of Oncology Data AdvisorTM, Shailender Bhatia, MD and Ciara Kelly, MBBCh, BAO discuss emerging evidence on immunotherapeutic strategies for advanced MCC and multidisciplinary approaches to monitor and manage immune-related adverse events. Listen now to earn CME/NCPD credit!
This episode of Oncology Data AdvisorTM with Daniel McFarland, DO, Northwell Health Lenox Hill Hospital, focuses on physician burnout, work-related stress, and the effects, including depression and exhaustion, that many physicians are facing from the challenges of the COVID-19 pandemic. Listen now to learn new strategies to combat these challenges and earn free CME!
This episode of Oncology Data Advisor TM focuses on the role of acquired resistance mutations in first-line treatment selection, the potential for central nervous system (CNS) disease, and the efficacy and safety of novel treatment options for patients with ALK-positive advanced NSCLC.